Skip to main content
. 2019 Jan 17;14(1):e0210796. doi: 10.1371/journal.pone.0210796

Fig 1. Impact of anti-CD200R antibodies (clone OX110) on the growth of EMT6 tumors.

Fig 1

(A) EMT6 tumor growth measured as a tumor volume. (B) Example of the gating strategy in flow cytometric analysis of the intratumoral immune cells. (C) Percentage of intratumoral myeloid cells (CD11b+) without neutrophils (Ly6G+). (D) Expression of CD200R in intratumoral immune cells. (E) Percentage of splenic myeloid cells from mice with EMT6 tumors, gating as in the tumors. (F) Expression of CD200R in splenic immune cells. Mice were treated with control or anti-CD200R antibodies (clone OX110). N = 7–8 / group, data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.